PO
PODD.US Insulet Corporation
- Market cap
- USD 10.1B
- P/E
- 23.7x
- P/B
- 6.38x
- ROE
- 27.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PODD.US undervalued?
Graham numberPODD.US trades 159.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Insulet Corporation fundamental analysis
No fundamental analysis for Insulet Corporation yet.
Insulet Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin m…
Full company profileInsulet Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Insulet Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 367M | 464M | 564M | 738M | 904M | 1.10B | 1.31B | 1.70B | 2.07B | 2.71B | 3.21B |
| Gross Profit | 211M | 277M | 370M | 480M | 582M | 752M | 806M | 1.16B | 1.45B | 1.94B | 2.30B |
| Operating Income | -10.7M | -7.39M | 27.4M | 50.0M | 51.5M | 126M | 37.6M | 220M | 309M | 474M | 589M |
| EBITDA | 1.40M | 6.47M | 43.1M | 74.2M | 110M | 140M | 109M | 324M | 424M | 510M | 669M |
| Net Income | -28.9M | -26.8M | 3.29M | 11.6M | 6.80M | 16.8M | 4.60M | 206M | 418M | 247M | 436M |
| EPS | -0.50 | -0.46 | 0.05 | 0.19 | 0.10 | 0.24 | 0.07 | 2.80 | 5.66 | 3.44 | 6.28 |
| Balance Sheet | |||||||||||
| Total Assets | 457M | 817M | 929M | 1.14B | 1.87B | 2.05B | 2.25B | 2.59B | 3.09B | 3.19B | 3.42B |
| Total Liabilities | 393M | 658M | 717M | 1.07B | 1.27B | 1.49B | 1.77B | 1.86B | 1.88B | 1.68B | 1.84B |
| Shareholders' Equity | 63.2M | 159M | 212M | 75.9M | 604M | 556M | 476M | 733M | 1.21B | 1.52B | 1.58B |
| Cash & Short-term Investments | 299M | 440M | 289M | 376M | 948M | 792M | 675M | 704M | 953M | 716M | 584M |
| Total Debt | 333M | 566M | 592M | 892M | 1.06B | 1.27B | 1.43B | 1.45B | 1.42B | 1.05B | 962M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 15.9M | 41.3M | 35.9M | 98.4M | 84.0M | -68.1M | 119M | 146M | 430M | 569M | 434M |
| Capital Expenditure | 22.1M | 77.2M | 162M | 171M | 167M | 123M | 157M | 75.6M | 125M | 192M | 152M |
| Free Cash Flow | -6.20M | -35.9M | -126M | -72.5M | -82.5M | -191M | -38.3M | 70.1M | 305M | 378M | 282M |
| Ratios | |||||||||||
| ROE | -45.7% | -16.9% | 1.6% | 15.3% | 1.1% | 3.0% | 1.0% | 28.2% | 34.5% | 16.3% | 27.6% |
| ROA | -6.3% | -3.3% | 0.4% | 1.0% | 0.4% | 0.8% | 0.2% | 8.0% | 13.5% | 7.7% | 12.8% |
| Net Profit Margin | -7.9% | -5.8% | 0.6% | 1.6% | 0.8% | 1.5% | 0.4% | 12.2% | 20.2% | 9.1% | 13.6% |
| Debt to Equity | 5.27x | 3.57x | 2.79x | 11.75x | 1.75x | 2.29x | 3.01x | 1.98x | 1.17x | 0.69x | 0.61x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Insulet Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 10.6M | 0.14 | 5.1% |
| 2022 | - | - | - |
| 2021 | USD 23.5M | 0.34 | 139.9% |
| 2020 | USD 98.5M | 1.49 | 1,448.5% |
| 2019 | USD 8.60M | 0.14 | 74.1% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Insulet Corporation
- Insiders 0.33%
- Institutions 99.67%
- Public & others 0.00%
- Shares outstanding 69.4M
- Free float 69.1M
Top funds holding PODD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.20M | 3.18% | +0.04% | Sep 2026 |
| Vanguard 500 Index Investor | 1.82M | 2.63% | -0.85% | Sep 2026 |
| Vanguard Small Cap Index | 1.56M | 2.25% | -2.01% | Sep 2026 |
| Invesco S&P 500® Equal Weight ETF | 1.43M | 2.06% | +0.17% | Oct 2026 |
| iShares Core S&P 500 ETF | 924K | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 901K | 1.30% | +0.24% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 868K | 1.25% | -5.15% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 847K | 1.22% | -0.25% | Oct 2026 |
| T. Rowe Price Mid-Cap Growth | 798K | 1.15% | 0.00% | Sep 2026 |
| Jupiter Merian Glb Eq Abs Rt I USD Acc | 557K | 0.80% | +46.76% | Jun 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 507K | 0.73% | +0.88% | Oct 2026 |
| MonumentItalnlvl1MSCIWdTrEURITL1WldE6441 | 486K | 0.70% | 0.00% | Oct 2026 |
| Federated Hermes MDT Mid Cap Growth A | 403K | 0.58% | -8.86% | Sep 2026 |
| iShares Russell Mid-Cap Growth ETF | 390K | 0.56% | -0.07% | Oct 2026 |
| Vanguard Institutional Index I | 367K | 0.53% | -0.58% | Sep 2026 |
| Fidelity World A-Dis-EUR | 336K | 0.48% | -0.10% | Sep 2026 |
| iShares US Medical Devices ETF | 331K | 0.48% | -1.12% | Oct 2026 |
| iShares Russell Mid-Cap ETF | 294K | 0.42% | -0.06% | Oct 2026 |
| ClearBridge Growth A | 283K | 0.41% | 0.00% | Sep 2026 |
| iShares Russell 1000 Growth ETF | 261K | 0.38% | +0.09% | Oct 2026 |
Top institutions holding PODD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 6.69M | 9.64% | +4.93% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.53M | 6.52% | -1.18% | Jun 2026 |
| State Street Corp | 3.20M | 4.61% | +5.10% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.08M | 4.43% | -10.84% | Jun 2026 |
| AQR Capital Management LLC | 2.46M | 3.54% | +53.57% | Jun 2026 |
| Geode Capital Management, LLC | 2.00M | 2.89% | -1.08% | Jun 2026 |
| Two Sigma Investments LLC | 1.90M | 2.74% | +149.72% | Jun 2026 |
| Amvescap Plc. | 1.69M | 2.44% | +54.55% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 1.51M | 2.18% | -16.72% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.48M | 2.13% | +29.07% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.47M | 2.12% | +19.61% | Jun 2026 |
| ClearBridge Advisors, LLC | 1.32M | 1.90% | -0.12% | Jun 2026 |
| Soleus Capital Management, L.P. | 1.05M | 1.51% | +86.49% | Jun 2026 |
| NORGES BANK | 1.05M | 1.51% | -0.97% | Jun 2026 |
| Jupiter Asset Management Limited | 1.03M | 1.48% | +44.62% | Jun 2026 |
| FMR Inc | 964K | 1.39% | -75.74% | Jun 2026 |
| Millennium Management LLC | 865K | 1.25% | +189.82% | Jun 2026 |
| Fidelity International Ltd | 840K | 1.21% | -16.99% | Jun 2026 |
| The Goldman Sachs Group Inc | 818K | 1.18% | -5.28% | Jun 2026 |
| Citadel Advisors Llc | 797K | 1.15% | +419.26% | Jun 2026 |
Insulet Corporation company profile
- Company name
- Insulet Corporation
- Ticker
- PODD.US
- Exchange
- USA Stocks
- Listed since
- May 15, 2007
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5,400
- Fiscal year end
- December
- Address
- 100 Nagog Park, Acton, MA, United States, 01720
- Phone
- 978 600 7000
- Website
- insulet.com
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insulet Corporation management
10- Ms. Ashley A. McEvoyCEO, President & Director · born 1971
- Ms. Flavia H. PeaseExecutive VP & CFO · born 1973
- Mr. Eric BenjaminExecutive VP & COO · born 1983
- Mr. John Wodick Kapples J.D.Senior VP & General Counsel · born 1960
- Mr. Prem SinghSenior Vice President of Global Operations · born 1977
- Mr. Amit GulianiSenior VP & CTO
- Ms. Clare TrachtmanVice President of Investor Relations
- Mr. Chuck MedovichSenior VP and Chief Quality, Regulatory & Compliance Officer
- Ms. Angela Geryak WiczekSenior Director of Corporate Communications
- Mr. Philip HildaleSenior Vice President of Sales & Customer Care